Jump to content

Category:Mood stabilizers: Difference between revisions

From Pharmacopedia
Replace stub with full Mood Stabilizers MedCategory page (first multi-vote on the wiki)
m CategoryClaude moved page Category:Mood Stabilizers to Category:Mood stabilizers: Sentence-case normalization per house style
 
(3 intermediate revisions by one other user not shown)
Line 1: Line 1:
The mood stabilizers are the class of medicines used to treat bipolar disorder to control the episodes of mania and depression that define the illness, and to prevent their return. The class is unusual in that it is defined less by a shared chemistry or mechanism than by a shared clinical purpose, and its founding member was discovered almost by accident, in a finding that opened the modern era of psychiatric medicine.
The '''mood stabilizers''' are the medicines used to treat bipolar disorder: to bring its episodes of mania and of depression under control, and to keep them from returning. The class is an unusual one, defined less by any shared chemistry or mechanism than by that shared clinical purpose, and its founding member was found very nearly by accident. In the late 1940s the Australian psychiatrist John Cade, working at a repatriation hospital outside Melbourne, was pursuing the idea that mania might be caused by some substance circulating in the body. He injected the urine of manic patients into guinea pigs, and, using a lithium salt merely as a way of dissolving a uric acid compound for the work, noticed that the lithium itself left the animals calm. In 1949 he published a small series in which lithium had produced striking improvement in patients with mania.<ref name="cade">Cade JF. Lithium salts in the treatment of psychotic excitement. ''The Medical Journal of Australia''. 1949 Sep 3;2(10):349–352. PMID: 18142718.</ref>


== John Cade and the discovery of lithium ==
The finding mattered well beyond the medicine itself. At a time when the serious mental illnesses were met chiefly with electroconvulsive therapy and with lobotomy, lithium was, in effect, the first medicine shown to treat a mental illness, and Cade's 1949 paper is often taken to mark the opening of modern psychopharmacology.<ref name="shorter">Shorter E. The history of lithium therapy. ''Bipolar Disorders''. 2009 Jun;11(Suppl 2):4–9. PMID: 19538681.</ref> Lithium in psychiatry was not, strictly, new, the American physician William Hammond had prescribed it for mania as early as 1871, only for the use to be forgotten, but it was Cade's work that carried it into modern medicine.
In the late 1940s the Australian psychiatrist John Cade was investigating a theory that mania might be caused by some substance circulating in the body. He injected urine from manic patients into guinea pigs, and — testing lithium merely as a way of making a uric acid compound soluble — found that lithium salts had a marked calming effect on the animals. In 1949 he published his observation that lithium produced striking improvement in a small group of patients with mania.<ref name="cade">Cade JF. Lithium salts in the treatment of psychotic excitement. ''Med J Aust.'' 1949;2(10):349–352. PMID 18142718.</ref>


The significance was larger than the drug itself. At a time when the main treatments for serious mental illness were electroconvulsive therapy and lobotomy, lithium was, in effect, the first medicine shown to treat a mental illness — and Cade's 1949 paper is often taken to mark the beginning of modern psychopharmacology.<ref name="shorter">Shorter E. The history of lithium therapy. ''Bipolar Disord.'' 2009;11(Suppl 2):4–9. PMID 19538681.</ref> Lithium's use in psychiatry was not, in fact, entirely new — the physician William Hammond had described lithium for mania as early as 1871, a use later forgotten — but it was Cade's work that brought it into modern medicine.
What followed was not the rapid success the discovery might seem to promise. Lithium is a simple element, it could not be patented, and it is toxic if not carefully dosed; deaths in the 1940s among people who had used lithium salts as a substitute for table salt had given it a frightening reputation. It was the Danish psychiatrist Mogens Schou who, from a controlled trial in 1954 onward, established lithium's worth, and then showed something more, that it could prevent episodes from returning rather than only treat them once they had come.<ref name="shorter"/> The United States was, strikingly, the fiftieth country to admit lithium to its market, in 1970.


Adoption was slow and uneven. Lithium is a simple element, could not be patented, and is toxic if not carefully dosed; early deaths from lithium used as a salt substitute had given it a poor reputation. It was the Danish psychiatrist Mogens Schou who, beginning with a controlled trial in 1954, established lithium's value and went on to show that it could also prevent episodes from recurring — not merely treat them.<ref name="shorter"/> The United States was, strikingly, the fiftieth country to admit lithium to its market, in 1970.
For years lithium stood almost alone. Then, from the 1960s and 1970s, several [[:Category:Anticonvulsants|anticonvulsants]] developed for epilepsy were found to control mania and to hold mood steady over the long term, [[valproic acid]] and [[carbamazepine]] among them, and later [[lamotrigine]], which worked best against the depressive side of the illness. From the 1990s a third group joined: several of the atypical antipsychotics proved effective against mania and, in some cases, in preventing relapse.<ref name="geddes">Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. ''Lancet''. 2013 May 11;381(9878):1672–1682. PMID: 23663953.</ref> The word "mood stabilizer" gathered these three unlike origins, an element, the anticonvulsants, the antipsychotics, under a single purpose. The word itself is recent: it was no part of psychiatry's vocabulary in lithium's early decades and spread only in the 1990s, its rise linked by historians in part to the marketing of valproic acid as an alternative to unpatentable lithium.<ref name="shorter"/> It has never been given a precise, agreed definition, and what should count as a mood stabilizer remains genuinely in dispute.


== A class assembles ==
Lithium remains, for many clinicians, the medicine against which the others are measured. It carries the strongest evidence for preventing relapse in bipolar disorder, and, alone among the mood stabilizers, it is associated with a lower risk of suicide; its use has nonetheless fallen in some countries, a decline often laid to the work of monitoring it and to the pull of newer, patentable medicines.<ref name="shorter"/> How the mood stabilizers work is, even now, not well understood, and because the class is gathered by clinical effect rather than by mechanism, its members share no single mode of action. This category collects the wiki's mood-stabilizer pages and groups them by their three origins.
For a long time lithium stood essentially alone. From the 1960s and 1970s, however, certain [[:Category:Anticonvulsants|anticonvulsants]] — medicines developed to treat epilepsy — were found also to control mania and to serve as long-term mood stabilizers, among them [[valproic acid]] (also formulated as divalproex) and [[carbamazepine]]. Later, [[lamotrigine]], another anticonvulsant, was found to be useful particularly against the depressive side of bipolar disorder.


From the 1990s a further group joined the class: several of the atypical antipsychotics — discussed more fully under [[:Category:Neuroleptics|neuroleptics]] — were shown to be effective against mania and, in some cases, in longer-term prevention.<ref name="geddes">Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. ''Lancet.'' 2013;381(9878):1672–1682. PMID 23663953.</ref> The medicines grouped as mood stabilizers thus come from three quite different origins — an element, the anticonvulsants, and the antipsychotics — united by their use in bipolar disorder rather than by any common structure.
== Mood stabilizers indexed ==


== What counts as a mood stabilizer ==
The medicines used as mood stabilizers come, unusually, from three quite different origins, united only by their use in bipolar disorder.
"Mood stabilizer" is a surprisingly recent term. It was not part of the vocabulary of psychiatry in the era of [[lithium]]'s discovery; it came into wide use only in the 1990s, and its spread has been linked by historians of medicine in part to the marketing of [[valproic acid]] as an alternative to [[lithium]] — lithium, an unpatentable element, being of little commercial interest to manufacturers.<ref name="shorter"/> The word, in other words, gained currency at least partly for reasons that were not purely clinical, and it has never since been given a precise, agreed definition.


Two broad views persist. A strict view holds that the name should be reserved for medicines that treat both mania and depression and prevent both from returning a demanding standard that few medicines fully meet. A looser view applies it to any medicine used in the long-term management of bipolar disorder. The medicines usually discussed under the term differ considerably in what they actually do: [[lithium]] acts against both poles and is the one agent nearly everyone includes; [[valproic acid]] and [[carbamazepine]] are stronger against mania; [[lamotrigine]] is the mirror case, acting mainly against the depressive phase; and the atypical antipsychotics are effective antimanic agents whose status as "mood stabilizers" rather than "antipsychotics used in bipolar disorder" is itself debated.
* '''Lithium''': [[lithium]], the element with which the class began, and still, for many clinicians, the standard against which the rest are measured.
* '''Anticonvulsant mood stabilizers''': [[valproic acid]], [[carbamazepine]], [[oxcarbazepine]], and [[lamotrigine]], medicines first developed for epilepsy and also indexed under [[:Category:Anticonvulsants|Anticonvulsants]]. Valproic acid and carbamazepine act most strongly against mania, lamotrigine against the depressive phase.
* '''Atypical antipsychotics used in bipolar disorder''': [[cariprazine]] and [[lumateperone]] are indexed here; several others, among them olanzapine, quetiapine, aripiprazole, and risperidone, serve as mood stabilizers as well and are indexed under [[:Category:Neuroleptics|Neuroleptics]].
 
== Notes on scope ==
 
This category indexes the mood stabilizers: the medicines used to control bipolar disorder and to prevent its episodes from returning. The boundary is unusually soft, because the class is defined by purpose rather than by chemistry, and what should count as a mood stabilizer has never had a settled answer.
 
Two views run alongside each other. A strict one reserves the name for medicines that act against both mania and depression and prevent both from returning, a standard that few medicines fully meet; a looser one applies it to any medicine used in the long-term management of bipolar disorder. The medicines usually discussed under the term differ widely in what they do: lithium acts against both poles and is the one agent nearly everyone includes; valproic acid and carbamazepine are stronger against mania; lamotrigine is the mirror case; and the atypical antipsychotics are effective antimanic agents whose standing as mood stabilizers, rather than as antipsychotics used in bipolar disorder, is itself debated.


<vote slug="moodstab-which-count" type="multi" options="Lithium; Valproate; Lamotrigine; Quetiapine/Olanzapine; Carbamazepine/Oxcarbazepine">Which medicines should count as mood stabilizers?</vote>
<vote slug="moodstab-which-count" type="multi" options="Lithium; Valproate; Lamotrigine; Quetiapine/Olanzapine; Carbamazepine/Oxcarbazepine">Which medicines should count as mood stabilizers?</vote>


== Lithium today ==
Following the wiki's multi-membership convention, the anticonvulsant mood stabilizers also appear under [[:Category:Anticonvulsants|Anticonvulsants]], and the antipsychotic ones under [[:Category:Neuroleptics|Neuroleptics]].
Despite the arrival of alternatives, lithium remains, for many clinicians, the standard against which other treatments for bipolar disorder are measured. It has the strongest evidence for preventing relapse, and — a property not clearly shown for the other mood stabilizers — it is associated with a reduction in the risk of suicide. Its use has nonetheless declined in some countries, a shift often attributed to the demands of monitoring it and to the marketing of newer, patentable medicines.<ref name="shorter"/> It continues to be widely regarded as a medicine whose value is not fully reflected in how often it is now prescribed.


== Mechanisms ==
== About these pages ==
How the mood stabilizers work is, even now, not well understood — and because the class is grouped by clinical effect rather than by mechanism, its members do not share a single mode of action. Lithium is known to affect a number of intracellular signalling systems, and is purported to act in part by modulating these pathways and by influencing the balance of excitatory and inhibitory neurotransmission, but no one mechanism has been established as responsible for its mood-stabilizing effect. The anticonvulsant mood stabilizers are understood to act on ion channels and on inhibitory neurotransmission, as described under [[:Category:Anticonvulsants|anticonvulsants]]; the atypical antipsychotics act on dopamine and serotonin receptors. That these medicines have these various actions is reasonably well established; the relationship between any of those actions and the stabilization of mood remains genuinely uncertain and a subject of active research.


== Members ==
Each mood stabilizer indexed here has its own page, built on the wiki's standard structure for a medicine: a history-first account, then pharmacology, indications, adverse effects, and interactions.
The medicines used as mood stabilizers fall into three groups. The first is [[lithium]] itself. The second is a group of [[:Category:Anticonvulsants|anticonvulsants]], chiefly [[valproic acid]], [[carbamazepine]], and [[lamotrigine]]. The third is a number of atypical antipsychotics — among them [[olanzapine]], [[quetiapine]], [[aripiprazole]], and [[risperidone]] — which are covered as a group under [[:Category:Neuroleptics|neuroleptics]]. The list is not exhaustive, and the boundaries of the class are, as noted above, not sharply drawn.


== Safety ==
This is one of the wiki's MedCategory class-overview pages. It carries the [[:Category:MedCategory|MedCategory]] and [[:Category:MedCategoryFull|MedCategoryFull]] marker tags; the second suppresses the member list that MediaWiki would otherwise generate automatically, leaving the curated index above as the only one the reader sees. The category sits beneath [[:Category:Medicines|Medicines]] and beneath [[:Category:Pharmaceutical|Pharmaceutical]], the origin category for medicines that came into use through scientific discovery rather than traditional practice; lithium reaches medicine as a pharmaceutical because it is an element, a mineral salt rather than a natural product of any living thing.
Because the mood stabilizers are a mixed group, their risks differ greatly from one medicine to another, and the safety information for each is best read on its own. Some general points can be made. [[Lithium]] has a narrow margin between an effective dose and a toxic one, so that treatment requires regular blood tests; over the long term it can affect the kidneys and the thyroid, which are also monitored. Several of the anticonvulsant mood stabilizers, [[valproic acid]] in particular, carry a substantial risk of birth defects and of effects on development when taken in pregnancy, and their use in people who may become pregnant has become increasingly restricted. The atypical antipsychotics carry their own characteristic risks, including metabolic effects such as weight gain. Across the class, mood-stabilizer treatment is generally long-term, and these medicines are not stopped abruptly without advice. Figures for all these risks are population estimates that vary between studies, and individual response varies considerably between people.


== References ==
== References ==
Line 38: Line 39:
[[Category:MedCategory]]
[[Category:MedCategory]]
[[Category:MedCategoryFull]]
[[Category:MedCategoryFull]]
[[Category:Medicines]]
[[Category:Pharmaceutical]]

Latest revision as of 05:02, 23 May 2026

The mood stabilizers are the medicines used to treat bipolar disorder: to bring its episodes of mania and of depression under control, and to keep them from returning. The class is an unusual one, defined less by any shared chemistry or mechanism than by that shared clinical purpose, and its founding member was found very nearly by accident. In the late 1940s the Australian psychiatrist John Cade, working at a repatriation hospital outside Melbourne, was pursuing the idea that mania might be caused by some substance circulating in the body. He injected the urine of manic patients into guinea pigs, and, using a lithium salt merely as a way of dissolving a uric acid compound for the work, noticed that the lithium itself left the animals calm. In 1949 he published a small series in which lithium had produced striking improvement in patients with mania.[1]

The finding mattered well beyond the medicine itself. At a time when the serious mental illnesses were met chiefly with electroconvulsive therapy and with lobotomy, lithium was, in effect, the first medicine shown to treat a mental illness, and Cade's 1949 paper is often taken to mark the opening of modern psychopharmacology.[2] Lithium in psychiatry was not, strictly, new, the American physician William Hammond had prescribed it for mania as early as 1871, only for the use to be forgotten, but it was Cade's work that carried it into modern medicine.

What followed was not the rapid success the discovery might seem to promise. Lithium is a simple element, it could not be patented, and it is toxic if not carefully dosed; deaths in the 1940s among people who had used lithium salts as a substitute for table salt had given it a frightening reputation. It was the Danish psychiatrist Mogens Schou who, from a controlled trial in 1954 onward, established lithium's worth, and then showed something more, that it could prevent episodes from returning rather than only treat them once they had come.[2] The United States was, strikingly, the fiftieth country to admit lithium to its market, in 1970.

For years lithium stood almost alone. Then, from the 1960s and 1970s, several anticonvulsants developed for epilepsy were found to control mania and to hold mood steady over the long term, valproic acid and carbamazepine among them, and later lamotrigine, which worked best against the depressive side of the illness. From the 1990s a third group joined: several of the atypical antipsychotics proved effective against mania and, in some cases, in preventing relapse.[3] The word "mood stabilizer" gathered these three unlike origins, an element, the anticonvulsants, the antipsychotics, under a single purpose. The word itself is recent: it was no part of psychiatry's vocabulary in lithium's early decades and spread only in the 1990s, its rise linked by historians in part to the marketing of valproic acid as an alternative to unpatentable lithium.[2] It has never been given a precise, agreed definition, and what should count as a mood stabilizer remains genuinely in dispute.

Lithium remains, for many clinicians, the medicine against which the others are measured. It carries the strongest evidence for preventing relapse in bipolar disorder, and, alone among the mood stabilizers, it is associated with a lower risk of suicide; its use has nonetheless fallen in some countries, a decline often laid to the work of monitoring it and to the pull of newer, patentable medicines.[2] How the mood stabilizers work is, even now, not well understood, and because the class is gathered by clinical effect rather than by mechanism, its members share no single mode of action. This category collects the wiki's mood-stabilizer pages and groups them by their three origins.

Mood stabilizers indexed

The medicines used as mood stabilizers come, unusually, from three quite different origins, united only by their use in bipolar disorder.

  • Lithium: lithium, the element with which the class began, and still, for many clinicians, the standard against which the rest are measured.
  • Anticonvulsant mood stabilizers: valproic acid, carbamazepine, oxcarbazepine, and lamotrigine, medicines first developed for epilepsy and also indexed under Anticonvulsants. Valproic acid and carbamazepine act most strongly against mania, lamotrigine against the depressive phase.
  • Atypical antipsychotics used in bipolar disorder: cariprazine and lumateperone are indexed here; several others, among them olanzapine, quetiapine, aripiprazole, and risperidone, serve as mood stabilizers as well and are indexed under Neuroleptics.

Notes on scope

This category indexes the mood stabilizers: the medicines used to control bipolar disorder and to prevent its episodes from returning. The boundary is unusually soft, because the class is defined by purpose rather than by chemistry, and what should count as a mood stabilizer has never had a settled answer.

Two views run alongside each other. A strict one reserves the name for medicines that act against both mania and depression and prevent both from returning, a standard that few medicines fully meet; a looser one applies it to any medicine used in the long-term management of bipolar disorder. The medicines usually discussed under the term differ widely in what they do: lithium acts against both poles and is the one agent nearly everyone includes; valproic acid and carbamazepine are stronger against mania; lamotrigine is the mirror case; and the atypical antipsychotics are effective antimanic agents whose standing as mood stabilizers, rather than as antipsychotics used in bipolar disorder, is itself debated.

Which medicines should count as mood stabilizers?
0

Following the wiki's multi-membership convention, the anticonvulsant mood stabilizers also appear under Anticonvulsants, and the antipsychotic ones under Neuroleptics.

About these pages

Each mood stabilizer indexed here has its own page, built on the wiki's standard structure for a medicine: a history-first account, then pharmacology, indications, adverse effects, and interactions.

This is one of the wiki's MedCategory class-overview pages. It carries the MedCategory and MedCategoryFull marker tags; the second suppresses the member list that MediaWiki would otherwise generate automatically, leaving the curated index above as the only one the reader sees. The category sits beneath Medicines and beneath Pharmaceutical, the origin category for medicines that came into use through scientific discovery rather than traditional practice; lithium reaches medicine as a pharmaceutical because it is an element, a mineral salt rather than a natural product of any living thing.

References

  1. Cade JF. Lithium salts in the treatment of psychotic excitement. The Medical Journal of Australia. 1949 Sep 3;2(10):349–352. PMID: 18142718.
  2. 2.0 2.1 2.2 2.3 Shorter E. The history of lithium therapy. Bipolar Disorders. 2009 Jun;11(Suppl 2):4–9. PMID: 19538681.
  3. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013 May 11;381(9878):1672–1682. PMID: 23663953.

Pages in category "Mood stabilizers"

The following 13 pages are in this category, out of 13 total.